Chong Kun Dang Pharmaceutical has received approval from South Korea's food and drug safety ministry to launch CKD-11101, a biosimilar of Amgen's Epogen, BusinessKorea reported.
The therapy, which was developed by Kyowa Hakko Kirin, is the first biosimilar of a novel erythropoiesis stimulating protein to gain approval anywhere globally.
Global sales of novel erythropoiesis stimulating proteins total nearly 3 trillion won annually.
Chong Kun Dang has additionally requested approval of CKD-11101 in Japan.
To read more NewsPoints articles, click here.